Scientific Reports (Aug 2024)

A methylation risk score for chronic kidney disease: a HyperGEN study

  • Alana C. Jones,
  • Amit Patki,
  • Vinodh Srinivasasainagendra,
  • Bertha A. Hidalgo,
  • Hemant K. Tiwari,
  • Nita A. Limdi,
  • Nicole D. Armstrong,
  • Ninad S. Chaudhary,
  • Bré Minniefield,
  • Devin Absher,
  • Donna K. Arnett,
  • Leslie A. Lange,
  • Ethan M. Lange,
  • Bessie A. Young,
  • Clarissa J. Diamantidis,
  • Stephen S. Rich,
  • Josyf C. Mychaleckyj,
  • Jerome I. Rotter,
  • Kent D. Taylor,
  • Holly J. Kramer,
  • Russell P. Tracy,
  • Peter Durda,
  • Silva Kasela,
  • Tuuli Lappalinen,
  • Yongmei Liu,
  • W. Craig Johnson,
  • David J. Van Den Berg,
  • Nora Franceschini,
  • Simin Liu,
  • Charles P. Mouton,
  • Parveen Bhatti,
  • Steve Horvath,
  • Eric A. Whitsel,
  • Marguerite R. Irvin

DOI
https://doi.org/10.1038/s41598-024-68470-z
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (CpG) sites, have been linked to kidney function and may have clinical utility in predicting the risk of CKD. Given the dynamic relationship between the epigenome, environment, and disease, AAs may be especially sensitive to environment-driven methylation alterations. Moreover, risk models incorporating CpG methylation have been shown to predict disease across multiple racial groups. In this study, we developed a methylation risk score (MRS) for CKD in cohorts of AAs. We selected nine CpG sites that were previously reported to be associated with estimated glomerular filtration rate (eGFR) in epigenome-wide association studies to construct a MRS in the Hypertension Genetic Epidemiology Network (HyperGEN). In logistic mixed models, the MRS was significantly associated with prevalent CKD and was robust to multiple sensitivity analyses, including CKD risk factors. There was modest replication in validation cohorts. In summary, we demonstrated that an eGFR-based CpG score is an independent predictor of prevalent CKD, suggesting that MRS should be further investigated for clinical utility in evaluating CKD risk and progression.

Keywords